SmartPeptide
Start Free
Fat LossLimited human evidence

CagriSema

Novo Nordisk's once-weekly combination of cagrilintide (an amylin analog) and semaglutide. Designed to combine appetite suppression (semaglutide) with satiety + meal-size regulation (cagrilintide). REDEFINE-1 Phase 3 showed ~22.7% weight loss at 68 weeks — strong but below pre-trial expectations.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

REDEFINE-1 (Phase 3, n≈3,400, 68 weeks): mean weight reduction of ~22.7% on CagriSema vs. ~16.1% on semaglutide alone and ~3% on placebo. Cardiovascular outcomes trial REDEFINE-3 is ongoing. Awaiting full FDA submission package.

What's still experimental

Not yet FDA-approved. The combination's performance vs. retatrutide in head-to-head comparisons is unknown. Optimal dosing and treatment duration are still being characterized. MASH and CV outcome data are pending.

Anecdotal / community reports

Available only through clinical trials. Forum speculation about 'building your own' by stacking compounded cagrilintide with semaglutide is dangerous — formulation stability, dose ratios, and interaction data are not established outside the Novo formulation.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “CagriSema”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “CagriSema”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
90
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
5
34 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "cagrisema OR cagrilintide semaglutide"

Europe PMC — 369 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
595
all years
Last 5 years
591
recent activity
Open access
539
freely readable
OA share
91%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “cagrisema OR (cagrilintide AND semaglutide)” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
6,269
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • Novo Nordisk198 works
  • Novo Nordisk A/S94 works
  • National Natural Science Foundation of China50 works
  • Eli Lilly and Company35 works
  • National Institutes of Health28 works
  • National Institute of Diabetes and Digestive and Kidney Diseases16 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 4 of 4 preprints indexed by Europe PMC.

Known risks

GI side effects (class-typical for GLP-1 + amylin combination). Pancreatitis signal (rare, class warning), gallbladder events. Not yet FDA-approved — long-term safety still being characterized.

Reported side effects

Nausea, vomiting, diarrhea, constipation, decreased appetite, injection-site reactions. The amylin component may add mild glucose-related effects.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “CagriSema”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Investigational only. Patients should pursue FDA-approved alternatives under prescriber care until approval.

Questions for your clinician

  • How does CagriSema compare to Retatrutide for my situation?
  • Should I wait for CagriSema approval or start on currently-approved options?
  • What baseline + monitoring labs would you recommend if I enroll in a trial?

Editorially curated references

Discussions about CagriSema

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all CagriSema discussions Native, moderated, no buying or selling